Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)

View ORCID ProfileIndraneel Mittra, Rosemarie de Souza, Rakesh Bhadade, Tushar Madke, P.D. Shankpal, Mohan Joshi, Burhanuddin Qayyumi, Atanu Bhattacharjee, Vikram Gota, Sudeep Gupta, Pankaj Chaturvedi, Rajendra Badwe
doi: https://doi.org/10.1101/2020.07.21.20151423
Indraneel Mittra
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Indraneel Mittra
Rosemarie de Souza
3BYL Nair Charitable Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rakesh Bhadade
3BYL Nair Charitable Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tushar Madke
3BYL Nair Charitable Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.D. Shankpal
3BYL Nair Charitable Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohan Joshi
3BYL Nair Charitable Hospital, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Burhanuddin Qayyumi
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atanu Bhattacharjee
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikram Gota
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudeep Gupta
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pankaj Chaturvedi
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajendra Badwe
1Tata Memorial Centre, Mumbai, India
2Homi Bhabha National Institute, Mumbai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: badwera@tmc.gov.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background To be universally applicable in treatment of severe COVID-19, novel therapies, especially those with little toxicity and low cost, are urgently needed. We report here the use of one such therapeutic combination involving two commonly used nutraceuticals, namely resveratrol and copper in patients with this disease. This study was prompted by pre-clinical reports that sepsis-related cytokine storm and fatality in mice can be prevented by oral administration of small quantities of resveratrol and copper. Since cytokine storm and sepsis are major causes of death in severe COVID-19, we retrospectively analyzed outcomes of patients with this condition who had received resveratrol and copper.

Methods & Findings Our analysis comprised of 230 patients with severe COVID-19 requiring inhaled oxygen who were admitted in a single tertiary care hospital in Mumbai between April 1 and May 13 2020. Thirty of these patients received, in addition to standard care, resveratrol and copper at doses of 5.6 mg and 560 ng, respectively, orally, once every 6 hours, until discharge or death. These doses were based on our pre-clinical studies, and were nearly 50 times and 2000 times less, respectively, than those recommended as health supplements. A multivariable-adjusted analysis was used to model the outcome of death in these patients and evaluate factors associated with this event. A binary logistic regression analysis was used, with age, sex, presence of comorbidities and receipt of resveratrol-copper as covariates. Data were updated as of May 30 2020. The number of deaths in resveratrol-copper and standard care only groups were 7/30 (23.3%, 95% CI 8.1%-38.4%) and 89/200 (44.5%, 95% CI 37.6%-51.3%), respectively. In multivariable analysis, age >50 years [odds ratio (OR) 2.558, 95% CI 1.454-4.302, P=0.0011] and female sex (OR 1.939, 95% CI 1.079-3.482, P=0.0267) were significantly associated, while presence of co-morbidities was not significantly associated (OR 0.713, 95% CI 0.405-1.256, P=0.2421) with death. There was a trend towards reduction in death in patients receiving resveratrol-copper (OR 0.413, 95% CI 0.164-1.039, P= 0.0604).

Conclusions We provide preliminary results of a novel approach to the treatment of severe COVID-19 using a combination of small amounts of commonly used nutraceuticals, which is non-toxic and inexpensive, and therefore could be widely accessible globally. The nearly two-fold reduction in mortality with resveratrol-copper observed in our study needs to be confirmed in a randomized controlled trial.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

Clinical Trials Registry of India; Registration Number CTRI/2020/06/026256

Clinical Protocols

http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45115&EncHid=&userName=Rosemarie%20desouza

Funding Statement

This study was supported by the Department of Atomic Energy, Government of India through its grant CTC to Tata Memorial Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This observational study was approved by the Ethics Committee of BYL Nair Hospital, Mumbai. The study is registered in the Clinical Trials Registry of India; Registration Number CTRI/2020/06/026256. The analysis was conducted adhering to ethical principles, including maintaining patient confidentiality. All authors vouch for the accuracy of data and analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All de-identified patient data used for analysis in this study is made available as table 2 in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
Indraneel Mittra, Rosemarie de Souza, Rakesh Bhadade, Tushar Madke, P.D. Shankpal, Mohan Joshi, Burhanuddin Qayyumi, Atanu Bhattacharjee, Vikram Gota, Sudeep Gupta, Pankaj Chaturvedi, Rajendra Badwe
medRxiv 2020.07.21.20151423; doi: https://doi.org/10.1101/2020.07.21.20151423
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002)
Indraneel Mittra, Rosemarie de Souza, Rakesh Bhadade, Tushar Madke, P.D. Shankpal, Mohan Joshi, Burhanuddin Qayyumi, Atanu Bhattacharjee, Vikram Gota, Sudeep Gupta, Pankaj Chaturvedi, Rajendra Badwe
medRxiv 2020.07.21.20151423; doi: https://doi.org/10.1101/2020.07.21.20151423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2647)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)